Adakveo (Crizanlizumab)

Novartis Sickle Cell drug gets U.S. FDA approval.

The Food and Drug Administration approved Novartis AG’s Adakveo (crizanlizumab) for patients 16 and older. The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly $85,000 to $113,000 per year, depending on dosing. Insured patients generally will pay less.

Read more at: